Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (52)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Redford, E. J.
Right arrow Articles by Hughes, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Redford, E. J.
Right arrow Articles by Hughes, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 120, Issue 10 1895-1905, Copyright © 1997 by Oxford University Press

ARTICLES

A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis

EJ Redford, KJ Smith, NA Gregson, M Davies, P Hughes, AJ Gearing, K Miller and RA Hughes
Department of Neurology, Medical School, London, UK.

Matrix metalloproteinases (MMPs) and the cytokine tumour necrosis factor (TNF)-alpha are implicated in the pathology of inflammatory demyelinating diseases of the CNS, and may also be involved in peripheral demyelinating diseases such as acute inflammatory demyelinating polyradiculoneuropathy. We have tested an inhibitor of MMP activity and TNF-alpha processing, BB-1101, in experimental autoimmune neuritis (EAN), an animal model of Guillain-Barre syndrome. Treatment with BB-1101 from the time of immunization prevented the development of EAN, and when given from the onset of symptoms, it significantly reduced disease severity. These results indicate that MMPs and/or TNF-alpha are involved in the pathogenesis of EAN, and that drugs of this type may have potential as novel therapeutic agents in the therapy of peripheral nervous system demyelinating diseases.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BrainHome page
R. Gold, C. Linington, and H. Lassmann
Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research
Brain, August 1, 2006; 129(8): 1953 - 1971.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Sharshar, M.-C. Durand, J.-P. Lefaucheur, F. Lofaso, J.-C. Raphael, R. K. Gherardi, and A. Creange
MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barre syndrome
Neurology, November 26, 2002; 59(10): 1649 - 1651.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Creange, T. Sharshar, T. Planchenault, C. Christov, F. Poron, J.-C. Raphael, and R. K. Gherardi
Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome
Neurology, November 1, 1999; 53(8): 1683 - 1683.
[Abstract] [Full Text]

Home page
 NeurologyHome page
B. C. Kieseier, T. Seifert, G. Giovannoni, and H.-P. Hartung
Matrix metalloproteinases in inflammatory demyelination: Targets for treatment
Neurology, July 1, 1999; 53(1): 20 - 20.
[Abstract] [Full Text]

Home page
 NeurologyHome page
D. Leppert, P. Hughes, S. Huber, B. Erne, C. Grygar, G. Said, K. M. Miller, A. J. Steck, A. Probst, and P. Fuhr
Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy
Neurology, July 1, 1999; 53(1): 62 - 62.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.